📰 Proportion Score News
Proportion Score News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Proportion Score. Real-time updates on events, politics, business and more.
May 1, 2024
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...
January 10, 2024
The anti-TIM3 monoclonal antibody, cobolimab utilized in combination with the anti-PD–1 antibody dostarlimab-gxly demonstrated promising signs of clinical activity and an acceptable safety profile across all dose levels in heavily pretreated patients with advanced/metastatic non–small cell lung cancer.
January 8, 2024
Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized...
October 24, 2023
Media Release Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer...
October 16, 2023
Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur...
August 10, 2023
10.08.2023 - - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients ...
May 25, 2023
Immutep, a clinical-stage biotech company developing immunotherapies for cancer and autoimmune disease, has announced encouraging new clinical data in first-line non-small cell lung cancer from INSIGHT-003.
May 18, 2023
Immutep Limited (NASDAQ: IMMP) flew by an impressive 122% at the time of writing after positive news on their Phase II trial.
May 17, 2023
Media Release Immuno-oncology combination of eftilagimod alpha and the leading anti-PD-1 therapy generates meaningful long-term survival in non-small cell lung cancer patients in Phase II TACTI-002... | May 17, 2023
March 31, 2023
Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care... | March 31, 2023